“Evaluation of the Safety Profile of an Electronic Vapour Product Used for Two Years by Smokers in a Real-life Setting” states that 209 volunteer smokers who used a particular cigalike for 24 months displayed no adverse symptoms. They undertook lung function, electrocardiogram results and were tested for urinary cotinine levels.
Tanvir Walele, Director of Scientific Affairs at Fontem Ventures, said in a press release: “This study shows that after two years of continual e-cigarette use, there were no signs of serious health complications in smokers. Clinical data over a two-year period gives us a much clearer picture about longer term vaping, and the potential implications for the health of smokers, so they can make an informed decision.”
Keen to reference more reliable sources, Walele went on to cite the Cochrane Review in a plea for special treatment: “Governments and policy-makers should ensure that regulatory frameworks reflect this emerging scientific consensus, as more long term research demonstrates the safety profile of e-cigarettes. This research suggests we need e-cigarette regulation that is not modeled on tobacco product regulation, but encourages innovation and compliance with robust product quality, manufacturing and safety standards.”
The report summarised: “No clinically relevant findings were observed, which indicates that Puritane™ product aerosol is well tolerated when used by smokers for up to two years.”
Although the findings mirror those from more independent researchers, and confirms anecdotal evidence found on the POTV forum, its source (and strong linking to a Big Tobacco brand) ultimately does vaping few favours.
Fewer favours are done by the sweeping (and probably wrong) generalisation the company promote through media contacts. “Scientists declare 'vaping is safe',” shouts one headline.
Tobacco Tactics write: “Fontem Ventures was set up in December 2012 as a wholly owned Dutch subsidiary to Imperial Tobacco to develop “non-tobacco consumer experiences”.